Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications

Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications Publisher Pubmed

Ala M^{1, 2} ; Mohammad Jafari R¹ ; Dehpour AR^{1, 2}

Show Affiliations

1. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, 13145-784, Iran
2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, 13145-784, Iran

Source: Fundamental and Clinical Pharmacology Published:2021

Abstract

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertension (PAH). Due to the distribution of phosphodiesterase (PDE) in almost all organs, maybe it effects other diseases. Hence, a great number of investigations began to understand the role of PDEi in different organs. Preliminary research on sildenafil in cell culture and animal models has yielded promising results. Soon, a greater number of animal researches and clinical trials joined them. The results disclosed sildenafil can have beneficial effects in each organ such as heart, liver, kidney, brain, and intestines. Furthermore, it has significantly improved the prognosis of organ ischemia in various animal models. Clinical trials in several diseases, such as recurrent spontaneous miscarriage, fatty liver disease, bronchopulmonary dysplasia (BPD), heart failure, and premature ejaculation (PE) brought promising results. Although some clinical trials are available on the effects of sildenafil on various diseases, further studies on humans are needed to consolidate the ultimate effects of sildenafil. The aim of this review was to describe the effects of sildenafil on each organ and explain its mechanisms of action. Further, other PDE inhibitors such as tadalafil and vardenafil have been briefly discussed in parts of this review. © 2020 Societe Francaise de Pharmacologie et de Therapeutique

Related Docs

View other Related Docs

1. How Do Phosphodiesterase-5 Inhibitors Affect Cancer? a Focus on Glioblastoma Multiforme, Pharmacological Reports (2022)

2. Oxytocinergic System Mediates the Proconvulsant Effects of Sildenafil: The Role of Calcineurin, Hormones and Behavior (2020)

3. Phosphodiesterase Inhibitors Say No to Alzheimer's Disease, Food and Chemical Toxicology (2019)

4. Sildenafil Enhances Cisplatin-Induced Apoptosis in Human Breast Adenocarcinoma Cells, Journal of Cancer Research and Therapeutics (2020)

5. Sildenafil Protective Effects on High Glucose-Induced Neurotoxicity in Pc12 Cells: The Role of Oxidative Stress, Apoptosis, and Inflammation Pathways in an in Vitro Cellular Model for Diabetic Neuropathy, Neurological Research (2018)

6. Protective Effects of Modafinil Administration on Testicular Torsion/Detorsion Damage in Rats, Experimental and Molecular Pathology (2019)

7. Sildenafil Improves Radiation-Induced Oral Mucositis by Attenuating Oxidative Stress, Nf-Κb, Erk and Jnk Signalling Pathways, Journal of Cellular and Molecular Medicine (2022)

8. Sildenafil in the Treatment of Pressure Ulcer: A Randomised Clinical Trial, International Wound Journal (2015)

Experts (# of related papers)

View all Related Experts

Ahmad Reza Dehpour (5)

Hossein Khalili (1)

Style	Citing Format
MLA	Ala M, Mohammad Jafari R, Dehpour AR. "Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications." Fundamental and Clinical Pharmacology, vol. 35, no. 2, 2021, pp. 235-259.
APA	Ala M, Mohammad Jafari R, Dehpour AR (2021). Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications. Fundamental and Clinical Pharmacology, 35(2), 235-259.
Chicago	Ala M, Mohammad Jafari R, Dehpour AR. "Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications." Fundamental and Clinical Pharmacology 35, no. 2 (2021): 235-259.
Harvard	Ala M, Mohammad Jafari R, Dehpour AR (2021) 'Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications', Fundamental and Clinical Pharmacology, 35(2), pp. 235-259.
Vancouver	Ala M, Mohammad Jafari R, Dehpour AR. Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications. Fundamental and Clinical Pharmacology. 2021;35(2):235-259.
BibTex	@article{ author = {Ala M and Mohammad Jafari R and Dehpour AR}, title = {Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications}, journal = {Fundamental and Clinical Pharmacology}, volume = {35}, number = {2}, pages = {235-259}, year = {2021} }
RIS	TY - JOUR AU - Ala M AU - Mohammad Jafari R AU - Dehpour AR TI - Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications JO - Fundamental and Clinical Pharmacology VL - 35 IS - 2 SP - 235 EP - 259 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract